Noticias de DNLI_US

Noticias del mercado

Últimas noticias sobre DNLI_US — 142 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: DNLI_US ✕ 142 resultados
25/03/2026 DNLI_US — BioWorld News
Early FDA wins: Corcept’s Lifyorli, Denali’s Avlayah
25/03/2026 DNLI_US — Investing.com
FDA approves Denali’s Hunter syndrome brain therapy AVLAYAH
25/03/2026 DNLI_US — Taiwan News ES ← EN
Denali Therapeutics anuncia la aprobación de la FDA de EE. UU. de AVLAYAH™ (tividenofusp alfa-eknm) para el tratamiento del síndrome de Hunter (MPS II)
25/03/2026 DNLI_US — BioSpace
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
25/03/2026 DNLI_US — Quiver Quantitative
Denali Therapeutics Receives FDA Approval for AVLAYAH™, First New Treatment for Hunter Syndrome in Nearly 20 Years
24/03/2026 DNLI_US — DirectorsTalk Interviews
Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring a 56% Potential Upside in Biotech Innovation
17/03/2026 DNLI_US — DirectorsTalk Interviews
Denali Therapeutics (DNLI) Stock Analysis: Assessing a 60% Upside Potential in Neurodegenerative Therapies
16/03/2026 DNLI_US — BioSpace
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection
13/03/2026 DNLI_US — Yahoo Finance
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed?
11/03/2026 DNLI_US — Yahoo Finance
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
11/03/2026 DNLI_US — TradingView
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
10/03/2026 DNLI_US — DirectorsTalk Interviews
Denali Therapeutics Inc. (DNLI) Stock Analysis: Navigating the Biotech Terrain with a 54.52% Potential Upside
09/03/2026 DNLI_US — Sahm
A Look At Denali Therapeutics (DNLI) Valuation After Wider Losses And New US$200 Million Shelf Registration
09/03/2026 DNLI_US — Benzinga ES ← EN
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics y otras grandes acciones suben
07/03/2026 DNLI_US — Stock Traders Daily
(DNLI) Price Dynamics and Execution-Aware Positioning
02/03/2026 DNLI_US — Investing.com
Jefferies reiterates Denali stock Buy rating on gene therapy outlook
27/02/2026 DNLI_US — Yahoo Finance
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
27/02/2026 DNLI_US — Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
26/02/2026 DNLI_US — Stock Titan
Denali Therapeutics (DNLI) widens 2025 loss but fortifies cash for key 2026 drug milestones
26/02/2026 DNLI_US — Stock Titan
Hunter syndrome drug nears April FDA call as Denali raises $475M

Página 7 de 8

keyboard_arrow_up